August 15, 2016 Tissue Regeneration Therapeutics Inc. (TRT) today announced that a team of Canadian researchers has for the first time shown that TRT’s engineered mesenchymal stromal cell product (eTXP) can be used to deliver therapeutically useful monoclonal antibodies (mAbs) more effectively than administration of the mAbs themselves. The study appears this month, as a featured paper, in the journal STEM CELLS Translational Medicine.
For the full release click here